Tscan Therapeutics Stock Price To Sales

TCRX Stock

USD 1.61 0.09 5.29%

Tscan Therapeutics fundamentals help investors to digest information that contributes to Tscan Therapeutics' financial success or failures. It also enables traders to predict the movement of Tscan Stock. The fundamental analysis module provides a way to measure Tscan Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tscan Therapeutics stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	120.90	86.63

Price To Sales Ratio is likely to drop to 86.63 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Tscan Therapeutics Company Price To Sales Analysis

Tscan Therapeutics' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Tscan Therapeutics Price To Sales

34.16 X

Most of Tscan Therapeutics' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tscan Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Tscan Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Tscan Therapeutics is extremely important. It helps to project a fair market value of Tscan Stock properly, considering its historical fundamentals such as Price To Sales. Since Tscan Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tscan Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tscan Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Term Debt	Property Plant Equipment	Common Stock	Capital Surpluse	Long Term Debt	Short Long Term Debt
Total Assets		0.93	0.88	0.78	-0.64	-0.92	0.85	0.69	0.94	0.99	0.99	0.86	0.73	0.99	0.79	0.31	-0.54
Total Stockholder Equity	0.93		0.94	0.77	-0.79	-0.94	0.76	0.53	1.0	0.93	0.93	0.79	0.73	0.93	0.81	0.48	-0.74
Net Tangible Assets	0.88	0.94		0.74	-0.81	-0.8	0.66	0.33	0.93	0.88	0.88	0.84	0.73	0.87	0.58	0.28	-0.51
Current Deferred Revenue	0.78	0.77	0.74		-0.68	-0.74	0.83	0.48	0.76	0.8	0.76	0.68	0.96	0.79	0.58	0.24	-0.46
Net Debt	-0.64	-0.79	-0.81	-0.68		0.59	-0.47	0.03	-0.75	-0.72	-0.72	-0.39	-0.62	-0.62	-0.58	-0.53	0.56
Retained Earnings	-0.92	-0.94	-0.8	-0.74	0.59		-0.85	-0.76	-0.96	-0.91	-0.9	-0.79	-0.71	-0.94	-0.89	-0.51	0.8
Accounts Payable	0.85	0.76	0.66	0.83	-0.47	-0.85		0.78	0.78	0.82	0.79	0.77	0.88	0.82	0.79	0.46	-0.57
Total Liab	0.69	0.53	0.33	0.48	0.03	-0.76	0.78		0.57	0.62	0.6	0.65	0.48	0.71	0.69	0.21	-0.46
Net Invested Capital	0.94	1.0	0.93	0.76	-0.75	-0.96	0.78	0.57		0.93	0.93	0.82	0.73	0.94	0.81	0.47	-0.75
Total Current Assets	0.99	0.93	0.88	0.8	-0.72	-0.91	0.82	0.62	0.93		1.0	0.78	0.72	0.98	0.81	0.35	-0.55
Net Working Capital	0.99	0.93	0.88	0.76	-0.72	-0.9	0.79	0.6	0.93	1.0		0.77	0.68	0.97	0.81	0.36	-0.55
Short Term Debt	0.86	0.79	0.84	0.68	-0.39	-0.79	0.77	0.65	0.82	0.78	0.77		0.72	0.86	0.5	0.05	-0.37
Property Plant Equipment	0.73	0.73	0.73	0.96	-0.62	-0.71	0.88	0.48	0.73	0.72	0.68	0.72		0.72	0.54	0.3	-0.47
Common Stock	0.99	0.93	0.87	0.79	-0.62	-0.94	0.82	0.71	0.94	0.98	0.97	0.86	0.72		0.78	0.27	-0.56
Capital Surpluse	0.79	0.81	0.58	0.58	-0.58	-0.89	0.79	0.69	0.81	0.81	0.81	0.5	0.54	0.78		0.77	-0.83
Long Term Debt	0.31	0.48	0.28	0.24	-0.53	-0.51	0.46	0.21	0.47	0.35	0.36	0.05	0.3	0.27	0.77		-0.81
Short Long Term Debt	-0.54	-0.74	-0.51	-0.46	0.56	0.8	-0.57	-0.46	-0.75	-0.55	-0.55	-0.37	-0.47	-0.56	-0.83	-0.81

Click cells to compare fundamentals

Tscan Price To Sales Historical Pattern

Today, most investors in Tscan Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tscan Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Tscan Therapeutics price to sales as a starting point in their analysis.

Tscan Therapeutics Price To Sales

Timeline

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Tscan Therapeutics

Price To Sales Ratio Over Time

Tscan Price To Sales Ratio

Price To Sales Ratio

86.63

At this time, Tscan Therapeutics' Price To Sales Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, Tscan Therapeutics has a Price To Sales of 34.1634 times. This is 59.64% higher than that of the Biotechnology sector and 65.28% lower than that of the Health Care industry. The price to sales for all United States stocks is 199.15% lower than that of the firm.

Tscan Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tscan Therapeutics' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tscan Therapeutics could also be used in its relative valuation, which is a method of valuing Tscan Therapeutics by comparing valuation metrics of similar companies.

Tscan Therapeutics is currently under evaluation in price to sales category among its peers.

Tscan Fundamentals

	Return On Equity	-0.65
	Return On Asset	-0.26
	Operating Margin	(55.21) %
	Current Valuation	(96.52 M)
	Shares Outstanding	52.31 M
	Shares Owned By Insiders	0.82 %
	Shares Owned By Institutions	90.58 %
	Number Of Shares Shorted	2 M
	Price To Earning	23.45 X
	Price To Book	0.40 X
	Price To Sales	34.16 X
	Revenue	2.82 M
	Gross Profit	(2.03 M)
	EBITDA	(119.74 M)
	Net Income	(127.5 M)
	Cash And Equivalents	125.6 M
	Cash Per Share	5.22 X
	Total Debt	65.31 M
	Debt To Equity	0.04 %
	Current Ratio	7.53 X
	Book Value Per Share	4.26 X
	Cash Flow From Operations	(110.82 M)
	Short Ratio	5.80 X
	Earnings Per Share	(1.14) X
	Target Price	9.71
	Number Of Employees	194
	Beta	0.91
	Market Capitalization	96.2 M
	Total Asset	371.12 M
	Retained Earnings	(375.1 M)
	Working Capital	256.77 M
	Net Asset	371.12 M

About Tscan Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Tscan Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tscan Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tscan Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC